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Regarding “Differential gene expression in human
abdominal aorta: Aneurysmal versus occlusive
disease”
In the article by Armstrong et al,1 the expression of 16 MMPs
was evaluated in both abdominal aortic aneurysm (AAA) and
arterial occlusive disease (AOD) specimens. In this paper, the
MMP-9 results overexpressed in both tissues. The remaining
MMPs revealed strikingly similar expression. Recently Carrel et al2
demonstrated that MMP-3 was overexpressed in AAA tissue sam-
ples and may be involved in aneurysm pathogenesis. These papers
prompted us to report our data on MMP-3 genotype in the two
groups of patients.
It is well known that the insertion/deletion mechanism of an
adenosine nucleotide (A) at –1171 bp in the MMP-3 gene pro-
moter sequence results in a polymorphism (5A/6A) in which the
transcriptional activity of the 5A homozygous is approximately
double that of the 6A homozygotes.3
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We genotyped for 5A/6A polymorphism on MMP-3 pro-
moter 58 patients with AAA, 57 with AOD, and 133 age-matched
and sex-matched healthy controls. All subjects were Italians.
The genotype distribution (AOD, 3 5A/5A, 27 5A/6A, 27
6A/6A; AAA, 10 5A/5A, 35 5A/6A, 13 6A/6A; Controls, 36
5A/5A, 59 5A/6A, 38 6A/6A) was significantly different among
AOD patients and both AAA patients (P  .007; 2, 9.69) and
controls (P  .001; 2, 13.44). No differences were observed
between AAA patients and controls (P  .11).
In AOD patients, the less expressive allele 6A was significantly
more represented than the wild type 5A (AOD, 0.71; versus AAA,
0.52; P  .0039; and versus controls, 0.51; P  .0002).
Our results confirm the Finnish ones that showed no MMP-3
genotype differences in AAA patients4 but, for the first time,
evidenced a significant high 6A frequency in AOD patients, in
whom atherosclerosis manifests by narrowing of the arterial lumen.
These results are consistent with the finding that 6A allele is
significantly more represented in subjects suffering from internal
carotid artery stenosis, another occlusive arterial disease.5 On this
basis, some evidence appears that studies should be carried out to
verify the hypothesis that the MMP-3 promoter polymorphism
5A/6A might be involved in AOD pathogenesis as a genetic
marker or new risk factor.
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